Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech Inc.

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Krystal Biotech today and set a price target of $364.00. According to ...

Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities

Analysts have been eager to weigh in on the Healthcare sector with new ratings on RxSight (RXST), Liquidia Technologies (LQDA) and Krystal Biotech ...

Analysts Conflicted on These Healthcare Names: RxSight (RXST), Liquidia Technologies (LQDA) and Krystal Biotech (KRYS)

Krystal Biotech, Inc. (($KRYS)) has held its Q1 earnings call. Read on for the main highlights of the call. Krystal Biotech’s latest earnings call ...

Krystal Biotech Earnings Call Highlights Profitable Growth

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Krystal Biotech, with a price target of $323.00. Accord...

Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Krystal Biotech (KRYS), Incyte (INCY) and Acurx Phar...

Market Cap	$5.74B	P/E Ratio	37.93
52W High	$319.48	52W Low	$123.03
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	48.7%	52W Position	91.4%
Overall Score	62	Value Score	65
Quality Score	60	Technical Score	63

EPS Current Est	$7.98	EPS Next Est	$10.52
EPS Growth Est	+31.8%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KRYS	$302.68	+1.08%	181.92K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KRYS	$302.68	+1.1%	181.92K
3
4
5
6

KRYS

KRYS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Krystal Biotech Inc. Data in Excel

Get Krystal Biotech Inc. Data in Excel